- Home
- TEAF vs CKPT Comparison
TEAF vs CKPT Comparison
Compare TEAF & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- CKPT
- Stock Information
- Founded
- TEAF 2017
- CKPT 2014
- Country
- TEAF United States
- CKPT United States
- Employees
- TEAF N/A
- CKPT N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- CKPT Health Care
- Exchange
- TEAF Nasdaq
- CKPT Nasdaq
- Market Cap
- TEAF 174.8M
- CKPT 172.4M
- IPO Year
- TEAF N/A
- CKPT 2017
- Fundamental
- Price
- TEAF $12.07
- CKPT $3.13
- Analyst Decision
- TEAF
- CKPT Strong Buy
- Analyst Count
- TEAF 0
- CKPT 3
- Target Price
- TEAF N/A
- CKPT $12.00
- AVG Volume (30 Days)
- TEAF 56.1K
- CKPT 753.4K
- Earning Date
- TEAF 01-01-0001
- CKPT 03-21-2025
- Dividend Yield
- TEAF 9.20%
- CKPT N/A
- EPS Growth
- TEAF N/A
- CKPT N/A
- EPS
- TEAF N/A
- CKPT N/A
- Revenue
- TEAF N/A
- CKPT $47,000.00
- Revenue This Year
- TEAF N/A
- CKPT N/A
- Revenue Next Year
- TEAF N/A
- CKPT $300,658.78
- P/E Ratio
- TEAF N/A
- CKPT N/A
- Revenue Growth
- TEAF N/A
- CKPT N/A
- 52 Week Low
- TEAF $11.11
- CKPT $1.38
- 52 Week High
- TEAF $13.30
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- TEAF 42.32
- CKPT 46.36
- Support Level
- TEAF $12.11
- CKPT $3.10
- Resistance Level
- TEAF $12.28
- CKPT $3.43
- Average True Range (ATR)
- TEAF 0.10
- CKPT 0.26
- MACD
- TEAF -0.00
- CKPT 0.00
- Stochastic Oscillator
- TEAF 24.73
- CKPT 33.03
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.